Controversies in Alzheimer's disease drug development

International Review of Psychiatry

Volumn 20, Issue 4, 2008, Pages 389-395

  Cummings, Jeffrey L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; PLACEBO; SELEGILINE;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DRUG DEVELOPMENT; HUMAN; MEMORY DISORDER; NONHUMAN; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PATIENT SATISFACTION; PERCEPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HUMANS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; RESEARCH DESIGN; UNITED STATES;

EID: 54249154592     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260802094548     Document Type: Review

References (22)

1. Chang, M., Chow, S. C., & Pong, A. (2006). Adaptive design in clinical research: Issues, opportunities, and recommendations. Journal of Biopharm Stat, 16, 299-309.
2. Cummings, J. L. (2007). Measuring disease modification in Alzheimer's disease. CNS Spectr, 12, 11-14.
3. Cummings, J., Doody, M., & Clark, C. (2007). Disease-modifying therapies for Alzheimer disease. Neurology, 69.
4. Doniger, G., Dwolatzky, T., Zucker, D. M., et al. (2006). Computerized cognitive testing battery identifies mild cognitive impairment and mild dementia even in the presence of depressive symptoms. American Journal of Alzheimer's Disease, 21, 28-36.
5. Dubois, B., Jacova, J., DeKosky, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734-746.
6. Engler, H., Forsperg, A., Almkvist, O., et al. (2006). Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 129, 2856-2866.
7. European Medicines Agency (2007). Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. CPMP/EWP/553/95 Rev. London: European Medicines Agency.
8. Harrison, J., Minassian, S. L., Jenkins, L., Black, R. S., Koller, M., & Grundman, M. (2007). A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol, 64, 1323-1329.
9. Hendrix, S., Gutin, A., Zavitz, K., Carron, G., Laughlin, M., & Horton, S. (2007). Modification of the staggered start and randomized withdrawal clinical trial designs: Toward a practical demonstration of disease modification in Alzheimer's disease. Alzheimer's and Dementia, 3, S160.
10. Jack, J. C. R., & Petersen, R. C. (2000). Structural imaging approaches to Alzheimer's Disease. In F. M. Scinto & K. R. Daffner (Eds.), Early diagnosis of Alzheimer's disease. Totowa, NJ: Humana Press Inc.
11. Katz, R. (2004). Biomarkers and surrogate markers: An FDA perspective. NeuroRx, 1, 189-195.
12. Mani, R. B. (2004). The evaluation of disease modifying therapies in Alzheimer's disease: A regulatory viewpoint. Stat Med, 23, 305-314.
13. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
14. Mohs, R. C., Kawas, C., & Carrillo, M. C. (2006). Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimer's and Dementia, 2, 131-139.
15. Petersen, R. C., Doody, R., Kurz, A., et al. (2001). Current concepts in mild cognitive impairment. Arch Neurol, 58, 1985-1992.
16. Petersen, R. C., Thomas, R. G., Grundman, M., et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine, 352, 2379-2388.
17. Rang, H. (2006). Drug discovery and development - Facts and figures. London: Churchill Livingstone Elsevier.
18. Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356-1364.
19. Sampaio, C. (2006). Alzheimer disease: Disease modifying trials - Where are we? Where do we need to go? A reflective paper. Journal of Nutrition, Health & Aging, 10, 113-115.
20. Sano, M., Ernesto, C., Thomas, R. G., et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine, 336, 1216-1222.
21. Verheijen, J., Huisman, L., van Lent, N., et al. (2006). Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clinical Chemistry, 52, 1168-1174.
22. Wang, S. J., Hung, H. M. J., Tsong, Y., & Cui, L. (2001). Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Stat Med, 20, 903-1912.